San Diego, CA – Viking Therapeutics recently held its Q2 2024 Earnings Conference Call, providing insights into the company’s financial results and the progress of its clinical programs. The call, led by Brian Lian, Viking’s President and CEO, and Greg Zante, the company’s CFO, highlighted significant achievements and milestones in the first half of 2024.

One of the key highlights included positive results from the Phase 2 VENTURE trial evaluating VK2735 for obesity treatment. The trial showed substantial reductions in body weight after 13 weeks of treatment. Additionally, promising results were reported from a Phase 1 trial assessing a novel oral formulation of VK2735 in healthy volunteers, indicating significant weight loss and tolerability after 28 days of dosing.

Viking also announced successful results from the 52-week histology outcomes of the Phase 2b VOYAGE trial evaluating VK2809 for NASH and fibrosis treatment. The study demonstrated improvements in NASH resolution rate, fibrosis, and a combination of both endpoints.

Furthermore, Viking presented preclinical data on dual amylin and calcitonin receptor agonists at the American Diabetes Association’s scientific sessions, showcasing positive effects on weight loss, food intake, and metabolic profile in animal models.

With a strong balance sheet of over $900 million in cash, Viking is well-positioned to advance its pipeline programs aggressively. The company plans to explore monthly dosing of VK2735 in future studies and initiate Phase 3 development for obesity treatment based on FDA feedback.

In conclusion, Viking’s intense activity and successful clinical trials in the first half of 2024 demonstrate the company’s commitment to innovation and advancing novel treatment options for obesity, NASH, and other metabolic disorders. The upcoming Phase 3 programs and partnerships reflect Viking’s dedication to delivering impactful therapies to patients in need.